The other regulated markets grew by 37% YoY with strong growth and market share increase in the UK, Europe and Australia. The company announced the approval to de-merge Stelis Biopharma into a standalone entity and publicly list the entity. We expect a revenue/PAT CAGR of 10%/28% over FY21E-FY23E on the...